Stem cell transplantation for lymphoproliferative disorders

Autologous stem cell transplantation (ASCT) is an effective therapy for B and T-cell non-Hodgkin and Hodgkin lymphomas, when used as consolidation in first complete remission, or as rescue therapy for primary refractory or relapsed disease. The indications and timing of ASCT should include consideration for the use of novel therapies including the use of chimeric antigen receptor T-cell (CART) therapy. However, pending trial results, SCT offers best chance of durable response or cure for many lymphomas, particularly diffuse large B-cell and Hodgkin lymphomas. Allogeneic SCT (AlloSCT) can be considered for patients whose disease has proven refractory to multiple lines of therapy and even ASCT, but it is important to note the high rate of associated nonrelapse mortality.